Xiaolin Wang

Xiaolin Wang is an accomplished professional in the field of clinical development and biostatistics, currently serving as Executive Vice President of Development and Clinical Development at REVOLUTION Medicines since March 2018. Prior experience includes leadership roles as Vice President of Biometrics at Acerta Pharma B.V. and various Vice President positions at Geron, where responsibilities encompassed Biometrics and Development Operations. Xiaolin Wang also held roles at Genentech, including Associate Director of Biostatistics. Educational credentials include a Doctor of Science in Biostatistics from Harvard University, a Master of Science from the University of Washington, and a Bachelor of Science from Peking University.